

December, 2006

Evolva raises CHF 12 million in new equity financing

Evolva SA has received binding commitments for CHF 12 million (USD 10.3 million) in a second round of its Series A financing. In March 2005, Evolva completed a first closing of CHF 21.5 million, led by Aravis. Co-investors were Novartis Ventures, Yamanouchi Ventures (now Astellas Ventures), APIDC-VC, Danish Innovation Investment, Seed Capital and VaekstFonden (now Sunstone Capital). Evolva has now raised an additional CHF 12 million from the same group of investors.

About Evolva. Evolva develops small molecule drugs based upon proprietary genetic chemistry technologies. Founded in 2004, it currently has pre-clinical stage compounds in the anti-infective and cardiovascular/metabolic disease space, and third party discovery collaborations in cancer, antiviral and immunomodulators. Evolva employs c. 70 people in Switzerland, India and Denmark. For more information see www.evolva.com (<http://www.evolva.com>).



Tel: +41 61 485 2000
Fax: +41 61 485 2001

General Enquiries:
info@evolva.com

Business Enquiries:
busdev@evolva.com

www.evolva.com